The Gynecomastia Study

Studying a side effect of Malawi’s standardized antiretroviral treatment for HIV

research-context Context


Gynecomastia – the swelling of breast tissue in boys and men – is a documented side effect of efavirenz, a medication used to treat HIV. There is only limited knowledge of how common this condition is within Africa, although it has been documented elsewhere around the world.

Gynecomastia was first reported in Malawi in 2014 after the introduction of a new HIV treatment regimen. Malawi newspapers published articles on the reported cases, describing them as common and debilitating.

The negative publicity raised concerns that male enrolment and adherence to HIV care and treatment regimen that include gynecomastia could be impacted. While gynecomastia cases are rare, the prevalence of the condition in males on antiretroviral therapy (ART) in Malawi is unknown and no specific local guidelines for management exist.

research-aim Aim


The cross-sectional study aims to determine the prevalence of and risk factors for gynecomastia among a sample size of 1,000 HIV+ men that are actively taking ART medication in Zomba, Malawi. The study will allow Dignitas and other partners to target intervention measures.

 research-sitesSite


research-timeline Timeline


March 2016 – August 2016

research-partnerships Partnerships


Funder: USAID-Malawi

Study Lead: Dignitas International

research-team Study Team


Professor Joep van Oosterhout

Principal Investigator, Dignitas

Dr Alemayehu Amberbir

Co- Investigator, Dignitas

Dr. Daniella Garone

Co-Investigator, Dignitas

Gabriel Mateyu

Co-Investigator, Dignitas

Aunex Kwekwesa

Co- Investigator, Dignitas

Yamikani Mataka

Co- Investigator, Dignitas

Jack Msonkho

Co- Investigator, Dignitas

Dr. Victor Singano

Study lead, Dignitas

research-info Contact


For more information, please contact Dr. Victor Singano at

v.singano@dignitasinternational.org


Add Call to Action

Donate Now

victoriaThe Gynecomastia Study